3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Plasma cell
1
Other hematologic neoplasm
1
Myeloid
1
Lymphoid
1
Gynecologic
1
Genitourinary
1
Dermatologic
1
CNS
1
Breast
1
Conditions
Leukemia, Myeloid, Acute
2
Congenital Abnormalities
2
Wilms Tumor
1
Thyroid Neoplasms
1
Testicular Neoplasms
1
Small Cell Lung Carcinoma
1
Sezary Syndrome
1
Recurrence
1
Prostatic Neoplasms
1
Primary Myelofibrosis
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pdgfra-Associated Chronic Eosinophilic Leukemia
1
Neutropenia
1
Neuroendocrine Tumors
1
Neuroblastoma
1
Myeloproliferative Disorders
1
Mycosis Fungoides
1
Multiple Myeloma
1
Lymphoma, T-Cell, Cutaneous
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Mantle-Cell
1
Lymphoma, Large-Cell, Immunoblastic
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, Follicular
1
Lymphoma, B-Cell, Marginal Zone
1
Leukemia, Neutrophilic, Chronic
1
Leukemia, Myelomonocytic, Juvenile
1
Leukemia, Myelomonocytic, Chronic
1
Leukemia, Myelomonocytic, Acute
1
Leukemia, Myeloid, Chronic-Phase
1
Interventions
Rituximab
205
Cyclophosphamide
178
Peripheral Blood Stem Cell Transplantation
93
Etoposide
91
fludarabine phosphate
86
Filgrastim
81
Melphalan
62
Vincristine
60
Mycophenolic Acid
58
Busulfan
58
Whole-Body Irradiation
57
Cytarabine
51
Radiotherapy
49
Doxorubicin
49
Cyclosporine
49
Tacrolimus
48
Granulocyte Colony-Stimulating Factor
48
Prednisone
46
fludarabine
45
Bendamustine Hydrochloride
45
Methotrexate
44
Carmustine
36
Antilymphocyte Serum
34
Dexamethasone
32
Bortezomib
29
Gemcitabine
27
ibritumomab tiuxetan
25
Methylprednisolone
23
sargramostim
22
Stem Cell Transplantation
22
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Lymphoma, Non-Hodgkin
×
Lithium Carbonate
×
Clear all
NCT00408681
2017-03-07
GVHD
Fred Hutchinson Cancer Center
Phase NA
Completed
20 enrolled
27 charts